CCM
TMO icon

Coldstream Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Coldstream Capital Management’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.55M Sell
11,059
-287
-3% -$138K 0.07% 148
2026
Q1 		$5.58M Sell
11,346
-722
-6% -$392K 0.07% 138
2025
Q4 		$6.99M Sell
12,068
-239
-2% -$135K 0.09% 123
2025
Q3 		$5.97M Buy
12,307
+1,631
+15% +$759K 0.08% 132
2025
Q2 		$4.33M Sell
10,676
-498
-4% -$208K 0.07% 156
2025
Q1 		$5.56M Buy
11,174
+1,290
+13% +$699K 0.12% 111
2024
Q4 		$5.14M Buy
9,884
+179
+2% +$98.4K 0.11% 119
2024
Q3 		$5.97M Buy
9,705
+995
+11% +$589K 0.13% 108
2024
Q2 		$4.82M Buy
8,710
+203
+2% +$116K 0.12% 112
2024
Q1 		$4.94M Buy
8,507
+1,075
+14% +$603K 0.13% 110
2023
Q4 		$3.94M Buy
7,432
+681
+10% +$330K 0.11% 114
2023
Q3 		$3.42M Sell
6,751
-235
-3% -$125K 0.11% 118
2023
Q2 		$3.64M Sell
6,986
-295
-4% -$159K 0.12% 119
2023
Q1 		$4.2M Sell
7,281
-135
-2% -$76.1K 0.14% 111
2022
Q4 		$4.08M Buy
+7,416
New +$3.93M 0.15% 110
2022
Q2 		$3.88M Buy
7,143
+1,110
+18% +$611K 0.15% 102
2022
Q1 		$3.56M Sell
6,033
-411
-6% -$236K 0.12% 106
2021
Q4 		$4.3M Buy
6,444
+3,428
+114% +$2.14M 0.14% 102
2021
Q3 		$1.33M Sell
3,016
-476
-14% -$261K 0.06% 142
2021
Q2 		$1.76M Buy
3,492
+209
+6% +$98.6K 0.07% 185
2021
Q1 		$1.5M Buy
3,283
+143
+5% +$68.3K 0.09% 121
2020
Q4 		$1.46M Buy
3,140
+503
+19% +$236K 0.09% 118
2020
Q3 		$1.17M Buy
2,637
+94
+4% +$38.8K 0.1% 110
2020
Q2 		$921K Buy
2,543
+132
+5% +$44.2K 0.08% 133
2020
Q1 		$684K Buy
2,411
+113
+5% +$35.6K 0.07% 141
2019
Q4 		$746K Buy
2,298
+157
+7% +$47.6K 0.06% 169
2019
Q3 		$624K Sell
2,141
-5
-0.2% -$1.43K 0.05% 178
2019
Q2 		$631K Buy
2,146
+216
+11% +$59.5K 0.05% 184
2019
Q1 		$528K Buy
1,930
+9
+0.5% +$2.24K 0.05% 191
2018
Q4 		$430K Buy
1,921
+985
+105% +$231K 0.04% 205
2018
Q3 		$228K Buy
+936
New +$215K 0.02% 316

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Coldstream Capital Management's TMO Position: Q2 2026 in Review

Coldstream Capital Management reduced its Thermo Fisher Scientific (TMO) stake by 2.5% in Q2 2026, selling an estimated $138K and leaving 11,059 shares worth $5.55M. The position accounts for 0.07% of the portfolio, ranked #148.

Coldstream Capital Management first reported a position in TMO in Q3 2018 and has held it in 31 quarters since. The position peaked at $6.99M in Q4 2025. 2,630 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Coldstream Capital Management held 11,059 shares of Thermo Fisher Scientific worth $5.55M as of Q2 2026.
  • Coldstream Capital Management sold 287 Thermo Fisher Scientific shares in Q2 2026, an estimated $138K.
  • Thermo Fisher Scientific made up 0.07% of Coldstream Capital Management's portfolio in Q2 2026, its #148 holding.
  • Coldstream Capital Management first reported a position in Thermo Fisher Scientific in Q3 2018 and has held it in 31 quarters since.
  • Coldstream Capital Management's Thermo Fisher Scientific position peaked at $6.99M in Q4 2025.
  • 2,630 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.